Activ Surgical Joins Qualcomm Smart Cities Accelerator Program

June 30, 2020

Activ Surgical, a digital surgery pioneer, today announced that it has joined the Qualcomm® Smart Cities Accelerator Program and is collaborating with Innominds on the development of next-generation surgical sensing capabilities that will usher in a new era of visibility and insights for surgeons around the world.

ActivSurgical notes as part of the Qualcomm® Advantage Network, the Qualcomm Smart Cities Accelerator Program is designed to connect cities, municipalities, government agencies and enterprises with an ecosystem of providers to help deliver greater efficiencies, cost savings, safety and sustainability. With proven expertise in commercially deployed solutions, program members include hardware and software providers, cloud solution providers, system integrators and design and manufacturing companies, as well as those offering end-to-end smart city solutions.

“We are humbled and honored to join the Qualcomm Smart Cities Accelerator Program, particularly as we begin to ramp up deployments of our surgical intelligence platform into healthcare systems across the U.S. this year,” said Todd Usen, CEO, Activ Surgical. “We share Qualcomm Technologies’ vision to empower global access to best-in-class surgery, regardless of geography.”

Activ Surgical’s participation in the program and collaboration with Qualcomm Technologies will help increase opportunities for healthcare systems in the U.S. and in global markets to leverage its newly announced ActivEdge platform. ActivEdge is an AI and machine-learning (ML) hardware-agnostic platform that enables existing surgical systems to see in real-time what humans cannot currently see, including blood flow. Participation in the Qualcomm Smart Cities Accelerator Program will give Activ Surgical critical access to hardware- and software-enabled communication tools and 5G networks that will help bring these insights to every operating room around the world.

“Digital healthcare and telemedicine are extremely important elements of our smart, connected world, and will only continue to grow in importance,” said Sanjeet Pandit, senior director, business development and head of smart cities, Qualcomm Technologies, Inc. “We are happy to include Activ Surgical in the Qualcomm Smart Cities Accelerator Program to help grow this vital area.”

Activ Surgicals’ membership in the Qualcomm Smart Cities Accelerator Program also links it with Innominds, a specialist full-cycle product engineering services company. Activ Surgical and Innominds are currently working on the development of an AI-powered camera that can be used in digital surgeries, as well as a solution for big data ingestion into the cloud. The collaboration is expected to drive transformation initiatives in data-driven, intelligent surgery by bringing together both companies’ expertise across ML, 5G, big-data analytics and advanced visualization solutions for surgery.

“We are excited to collaborate with Innominds as part of the Qualcomm Smart Cities Accelerator Program,” said Tom Calef, CTO, Activ Surgical. “Our work will ensure that surgeons everywhere will have greater access to cutting-edge technologies that enable them to make better-informed decisions and ultimately make a greater impact on reducing the number of avoidable surgical errors that occur each day.”

“Working with Activ Surgical enables Innominds to bring together leading-edge device engineering, breakthrough software product engineering, cloud applications and AI-driven data engineering to power digital surgeries of the future,” said Anil Katakam, Chief Operating Officer, Innominds. “This collaboration will ensure that we stay at the forefront of developing AI-powered, connected camera/imaging solutions that are simpler, smarter and more cost-effective. This is a firm step in our endeavor to power the digital next initiatives of global companies that we work with.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version